MX2022011064A - Metodos para disminuir la incidencia de la enterocolitis necrotizante en bebes, infantes, o ni?os al usar los oligosacaridos de leche humana. - Google Patents

Metodos para disminuir la incidencia de la enterocolitis necrotizante en bebes, infantes, o ni?os al usar los oligosacaridos de leche humana.

Info

Publication number
MX2022011064A
MX2022011064A MX2022011064A MX2022011064A MX2022011064A MX 2022011064 A MX2022011064 A MX 2022011064A MX 2022011064 A MX2022011064 A MX 2022011064A MX 2022011064 A MX2022011064 A MX 2022011064A MX 2022011064 A MX2022011064 A MX 2022011064A
Authority
MX
Mexico
Prior art keywords
incidence
human milk
methods
milk oligosaccharides
toddlers
Prior art date
Application number
MX2022011064A
Other languages
English (en)
Inventor
Steven R Davis
Rachael Buck
Geralyn O Duska-Mcewen
Jomay Chow
Hawley K Linke
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2022011064A publication Critical patent/MX2022011064A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Pediatric Medicine (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)

Abstract

Se describen los métodos para reducir la incidencia de la enterocolitis necrotizante en un bebé, un infante, o un niño al usar las composiciones nutricionales que incluyen los oligosacáridos de leche humana. Las composiciones nutricionales que incluyen los oligosacáridos de leche humana son eficaces en la reducción de la inflamación y de la incidencia de las enfermedades inflamatorias.
MX2022011064A 2010-12-31 2013-06-28 Metodos para disminuir la incidencia de la enterocolitis necrotizante en bebes, infantes, o ni?os al usar los oligosacaridos de leche humana. MX2022011064A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061428863P 2010-12-31 2010-12-31
US201061428868P 2010-12-31 2010-12-31

Publications (1)

Publication Number Publication Date
MX2022011064A true MX2022011064A (es) 2022-10-07

Family

ID=45509697

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2013007692A MX2013007692A (es) 2010-12-31 2011-12-22 Metodos para disminuir la incidencia de la enterocolitis necrotizante en bebes, infantes, o niños al usar los oligosacaridos de leche humana.
MX2022011064A MX2022011064A (es) 2010-12-31 2013-06-28 Metodos para disminuir la incidencia de la enterocolitis necrotizante en bebes, infantes, o ni?os al usar los oligosacaridos de leche humana.
MX2020010780A MX2020010780A (es) 2010-12-31 2013-06-28 Métodos para disminuir la incidencia de la enterocolitis necrotizante en bebés, infantes, o niños al usar los oligosacáridos de leche humana.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013007692A MX2013007692A (es) 2010-12-31 2011-12-22 Metodos para disminuir la incidencia de la enterocolitis necrotizante en bebes, infantes, o niños al usar los oligosacaridos de leche humana.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020010780A MX2020010780A (es) 2010-12-31 2013-06-28 Métodos para disminuir la incidencia de la enterocolitis necrotizante en bebés, infantes, o niños al usar los oligosacáridos de leche humana.

Country Status (10)

Country Link
US (5) US9539269B2 (es)
EP (1) EP2658547A1 (es)
CN (1) CN107019701B (es)
BR (1) BR112013016905A2 (es)
CA (1) CA2822219C (es)
MX (3) MX2013007692A (es)
MY (2) MY197622A (es)
NZ (1) NZ611807A (es)
SG (3) SG191392A1 (es)
WO (1) WO2012092156A1 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754126B2 (en) 2010-12-29 2014-06-17 Abbott Laboratories Methods for improving tolerance, digestion, and lipid soluble nutrient absorption in an infant, toddler, or child
MY197622A (en) 2010-12-31 2023-06-28 Abbott Lab Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
SG191394A1 (en) 2010-12-31 2013-08-30 Abbott Lab Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
MY182335A (en) 2011-07-22 2021-01-19 Abbott Lab Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
US10639319B2 (en) 2011-08-29 2020-05-05 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
EP2836218A4 (en) * 2012-04-13 2015-10-21 Trustees Boston College PROBIOTIC COMPOSITIONS AND METHODS OF USE
EP2708145B1 (en) 2012-09-14 2016-05-04 Abbott Laboratories Nutritional compositions for use in methods for modulating corticosterone levels in psychologically stressed individuals
DK2708147T3 (da) * 2012-09-14 2020-05-18 Abbott Lab Fremgangsmåder til forøgelse af hjernefunktionalitet under anvendelse af 2-fucosyl-lactose
FR2997819B1 (fr) * 2012-11-14 2015-06-26 Roquette Freres Utilisation de polysaccharides dans le bien etre intestinal du nourisson et/ou du jeune enfant
WO2014100022A1 (en) * 2012-12-18 2014-06-26 Abbott Laboratories Dietary oligosaccharides to enhance learning and memory
WO2014100126A1 (en) * 2012-12-18 2014-06-26 Abbott Laboratories Human milk oligosaccharides to ameliorate symptoms of stress
CN110679948A (zh) * 2012-12-20 2020-01-14 雅培制药有限公司 使用人乳寡糖用于调节炎症的营养制剂
US9820504B2 (en) 2013-03-08 2017-11-21 Axiom Foods, Inc. Rice protein supplement and methods of use thereof
WO2014138304A1 (en) 2013-03-08 2014-09-12 Axiom Foods, Inc., Rice protein supplements
US9352020B2 (en) * 2013-03-15 2016-05-31 Mead Johnson Nutrition Company Reducing proinflammatory response
MX2013003636A (es) * 2013-03-27 2014-09-29 Palsgaard Ind De Mexico S De R L De C V Complemento alimenticio para personas con trisomia 21, transtorno del espectro autista y/o transtorno por deficit de atencion con o sin hiperactividad.
ES2916813T3 (es) * 2013-11-15 2022-07-06 Nestle Sa Composiciones para uso en la prevención o tratamiento de enterocolitis necrotizante en lactantes y niños pequeños
MX2016006221A (es) * 2013-11-15 2016-08-08 Nestec Sa Composiciones para usar en la prevencion o tratamiento de la enterocolitis necrotizante en infantes y niños pequeños.
US10940158B2 (en) 2013-11-15 2021-03-09 Societe Des Produits Nestle S.A. Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants or young children born by C-section
WO2015077233A1 (en) * 2013-11-19 2015-05-28 Abbott Laboratories Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides
EP2888950A1 (en) * 2013-12-24 2015-07-01 Abbott Laboratories Methods for treating, preventing, or reducing neuroinflammation or cognitive impairment
MX2016013064A (es) 2014-04-08 2017-01-26 Abbott Lab Metodos para mejorar las respuestas inmune innata y/o deteccion de patogenos de la mucosa mediante oligosacaridos de la leche humana.
US20150305385A1 (en) * 2014-04-25 2015-10-29 Mead Johnson Nutrition Company Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics
MX2017003441A (es) 2014-09-25 2017-06-20 Nestec Sa Sistema de formulas infantiles con niveles adaptables de oligosacaridos de la leche humana (hmo).
US11040050B2 (en) 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
EP3212198B1 (en) * 2014-10-29 2020-12-23 Glycom A/S Synthetic composition and method for promoting mucosal healing
US11040049B2 (en) 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
US20160346303A1 (en) 2014-10-29 2016-12-01 Glycom A/S Synthetic composition and method for treating irritable bowel syndrome
US10328091B2 (en) 2014-10-31 2019-06-25 Nestec S.A. Composition comprising Fut2-dependent oligosaccharides and Lacto-N-neotetraose for use in promoting brain development and cognition
WO2016086151A1 (en) * 2014-11-26 2016-06-02 Abbott Laboratories Infant formula with rrr-alpha-tocopherol, 2'-fucosyllactose, and a probiotic
EP3264920B1 (en) 2015-03-05 2020-12-16 Société des Produits Nestlé S.A. Compositions for use in the prevention or treatment of otitis or bronchitis in infants or young children
EP3265099B1 (en) * 2015-03-05 2023-08-09 Glycom A/S Human milk oligosaccharides for treating acute respiratory tract infections
WO2016139330A1 (en) * 2015-03-05 2016-09-09 Nestec S.A. Compositions for use in improving stool consistency or frequency in infants or young children
EP4226927A1 (en) 2015-03-05 2023-08-16 Société des Produits Nestlé S.A. Compositions for use in the prevention or treatment of gastrointestinal infections in infants or young children
CN107847509B (zh) 2015-08-04 2021-06-01 雀巢产品有限公司 具有2FL和LNnT的营养组合物
US11224605B2 (en) 2016-05-19 2022-01-18 Glycom A/S Synthetic composition
CN109475169A (zh) 2016-07-01 2019-03-15 进化生物系统股份有限公司 促进哺乳动物免疫系统成熟的方法
EP3493817A1 (en) * 2016-08-04 2019-06-12 Nestec S.A. Nutritional compositions with 2fl and lnnt for use in preventing and/or treating non-rotavirus diarrhea by acting on the gut microbiota dysbiosis
US20180064739A1 (en) * 2016-09-06 2018-03-08 Mead Johnson Nutrition Company Nutritional composition with human milk oligosaccharides and uses thereof
WO2018067923A1 (en) * 2016-10-06 2018-04-12 Tallgrass Therapeutics, Llc Compositions and methods for the prevention and treatment of colitis in infants
WO2018209131A1 (en) 2017-05-12 2018-11-15 Axiom Foods, Inc. Rice products and systems and methods for making thereof
EP3630123A4 (en) * 2017-05-24 2020-10-28 Glycom A/S SYNTHETIC COMPOSITION WITH ONE OR MORE HUMAN MILK OLIGOSACCHARIDES (HMOS)
US11541068B2 (en) * 2017-05-24 2023-01-03 Glycom A/S HMO compositions and methods for reducing autism spectrum disorder symptoms
MX2019015768A (es) 2017-06-21 2020-08-03 Abbott Lab Metodos para aumentar el crecimiento de las bacterias beneficiosas en el tracto gastrointestinal.
AU2018295414A1 (en) * 2017-07-07 2020-01-16 Societe Des Produits Nestle S.A. Human milk fortifier
US20200281245A1 (en) * 2017-07-07 2020-09-10 Societe Des Products Nestle S.A Human milk fortifier
CN107467677A (zh) * 2017-08-22 2017-12-15 北京特食生物科技研究中心（有限合伙） 一种润肠通便、维持肠道健康的复合营养品及其制备方法与应用
JP7327724B2 (ja) * 2017-11-30 2023-08-16 グリコム・アクティーゼルスカブ 小麦過敏症を処置するためのｈｍｏの混合物
MX2020007214A (es) * 2017-12-21 2020-09-07 Nestle Sa Composiciones para usar en la promocion del crecimiento y desarrollo de los musculos intestinales y la motilidad intestinal asociada.
GB2573539A (en) * 2018-05-09 2019-11-13 Mjn Us Holdings Llc Wellbeing supplement for postpartum maternal nutrition
CN111248289B (zh) * 2018-11-30 2023-04-07 内蒙古伊利实业集团股份有限公司 一种组合物、其制备方法及用途
WO2020159357A1 (en) 2019-02-01 2020-08-06 N.V. Nutricia Native whey protein for treating and/or preventing intestinal infection
US12005083B1 (en) 2019-06-24 2024-06-11 PBM Nutritionals, LLC Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof
US11849747B1 (en) 2019-06-24 2023-12-26 PBM Nutritionals, LLC Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof
JP7474596B2 (ja) * 2020-01-20 2024-04-25 森永乳業株式会社 新規ビフィドバクテリウム属細菌、および当該細菌を含む組成物、並びに当該細菌の増殖促進用の組成物
CN112870234B (zh) * 2021-01-27 2023-06-02 四川九章生物科技有限公司 包含绿原酸的药物组合物在制备治疗病理性黄疸的药物中的用途
CN113273695B (zh) * 2021-06-03 2022-05-17 海普诺凯营养品有限公司 一种改善新生儿溶血性高胆红素血症的组合物

Family Cites Families (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4762822A (en) 1985-08-08 1988-08-09 Ettinger Anna C Reduction of gastrointestinal disease-producing organisms with sialic acid and gangliosides
US5260280A (en) 1989-02-07 1993-11-09 Snow Brand Milk Products Co., Ltd. Bacterial toxin neutralizer
JPH03266255A (ja) 1990-03-15 1991-11-27 Canon Inc オートチェンジャ
US5013569A (en) * 1990-05-21 1991-05-07 Century Laboratories, Inc. Infant formula
SE468536B (sv) 1991-07-03 1993-02-01 Bolin Mauritz Ingf Ab Stickkontakt
DE69530910D1 (de) 1994-07-15 2003-07-03 Taiyo Kagaku Co Medizinische zusammensetzungen enthaltend ein sialinsäurederivat
JPH08266255A (ja) 1995-03-30 1996-10-15 Taiyo Kagaku Co Ltd 学習能力向上組成物
WO1997048388A1 (en) 1996-06-17 1997-12-24 The Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
JP3552856B2 (ja) 1996-09-27 2004-08-11 雪印乳業株式会社 栄養強化組成物
DE19701382A1 (de) 1997-01-16 1998-07-23 Nutricia Nv Kohlenhydratmischung
US6080787A (en) 1997-02-21 2000-06-27 Abbott Laboratories Methods for reducing the incidence of necrotizing enterocolitis
SK112399A3 (en) 1997-02-21 2000-12-11 Abbott Lab Methods and compositions for reducing the incidence of necrotizing enterocolitis
SA98190002B1 (ar) 1997-03-28 2006-06-20 ذي يونيفيرسيتي اوف تننيسي ريسيرش كوربوريشن استخدام أحماض دهنية تحتوي على عدة روابط غير مشبعة polyunsaturated fatty acids لتقليل حدوث الالتهاب المعوي القولوني الناخر incidence of necrotizing enterocolitis
US6045854A (en) * 1997-03-31 2000-04-04 Abbott Laboraties Nutritional formulations containing oligosaccharides
US5906982A (en) 1997-03-31 1999-05-25 Abbott Laboratories Nutritional formulations containing Lacto-N-neoTetraose
JPH10327804A (ja) 1997-06-04 1998-12-15 Meiji Milk Prod Co Ltd 核酸関連物質、ｄｈａ、アラキドン酸及び コレステロール含有栄養組成物
US20020019991A1 (en) 1998-04-30 2002-02-14 Abbott Laboratories Compositions containing an alpha 1,2-fucose linkage and uses thereof
US6294206B1 (en) 1999-04-09 2001-09-25 Abbott Laboratories Powdered human milk fortifier
US6497908B1 (en) 1999-07-19 2002-12-24 Seiri Oshiro Turmeric-containing cooking oils and fats
DE19958985A1 (de) 1999-12-07 2001-06-13 Nutricia Nv Oligosaccharidmischung
US6365218B1 (en) 2000-02-04 2002-04-02 Abbott Laboratories Pediatric formula and methods for providing nutrition and improving tolerance
TWI265008B (en) 2000-02-17 2006-11-01 Wyeth Corp Nutritional formulation comprising oligofructose and sialyllactose
US6630452B2 (en) 2000-02-17 2003-10-07 Wyeth Nutritional formulation containing prebiotic substances
FI110668B (fi) 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
US7090862B2 (en) 2001-03-30 2006-08-15 Abbott Laboratories Method of improving the antioxidant status of an infant
AU2002320251A1 (en) 2001-07-05 2003-01-21 Vital Basics, Inc. Compositions for improving mental performance
DE10147100A1 (de) 2001-09-25 2003-04-17 Numico Res B V Antiinfektive Kohlenhydrate
US6811801B2 (en) 2001-12-12 2004-11-02 Abbott Laboratories Methods and compositions for brightening the color of thermally processed nutritionals
DE10204000A1 (de) 2002-02-01 2003-08-14 Nutricia Nv Sialysierte Kohlenhydrate
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
AR039170A1 (es) 2002-03-28 2005-02-09 Bio Dar Ltd Co-granulos de dha y romero y metodos de uso
US20040001817A1 (en) 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
AU2003282494A1 (en) 2002-10-11 2004-05-04 Wyeth Nutritional formulations containing synbiotic substances
FI20021989A0 (fi) 2002-11-06 2002-11-06 Halina Miller-Podraza Korkean affiniteetin Helicobacter pylori-reseptorit ja niiden käyttö
DK1567117T3 (da) 2002-11-26 2012-05-21 Univ Chicago Forebyggelse og behandling af mikrobe-medierede epitelsygdomme
GB0229015D0 (en) 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound
US7867541B2 (en) 2003-04-14 2011-01-11 Mead Johnson Nutrition Company Compositions and methods of formulation for enteral formulas containing sialic acid
US7951410B2 (en) 2003-04-14 2011-05-31 Mead Johnson Nutrition Company Enteral compositions containing caseinoglycomacropeptide having an enhanced concentration of sialic acid
PL1638416T3 (pl) 2003-06-23 2013-09-30 Nestec Sa Zastosowanie żywnościowego preparatu do optymalizowania działania bariery jelitowej
WO2005000040A1 (en) 2003-06-24 2005-01-06 University Of Kansas Medical Center Infant formula
MXPA06006392A (es) * 2003-12-05 2007-03-15 Childrens Hosp Medical Center Composiciones de oligosacaridos y uso de estas en el tratamiento de infecciones.
US20060039954A1 (en) 2003-12-23 2006-02-23 Gierhart Dennis L Ocular formulations with neuroprotectants to reduce Alzheimer and neurotoxic risks created by large zinc dosages
US7416752B2 (en) 2004-01-06 2008-08-26 Sharp Ingrained Functional Foods, Inc. Method of fortifying seeds with an essential fatty acid, fortified seed and food product
ES1056525Y (es) 2004-01-13 2004-07-16 Perez Alfredo Pineiro Halador de tres rodillos para redes y aparejos de pesca.
US7851451B2 (en) 2004-03-12 2010-12-14 Mti Meta Tech Inc. Formulations for mediating inflammatory bowel disorders
US7090879B2 (en) 2004-03-18 2006-08-15 Abbott Laboratories Nutritional formula containing select carotenoid combinations
EP1597978A1 (en) 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
US8252769B2 (en) 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
US20080015166A1 (en) 2004-06-22 2008-01-17 N.V. Nutricia Barrier Integrity in Hiv Patients
EP1721611A1 (en) 2005-04-21 2006-11-15 N.V. Nutricia Nutritional supplement with oligosaccharides for a category of HIV patients
FR2872047B1 (fr) 2004-06-23 2007-06-15 Oreal Composition pour peaux sensibles associant cation mineral et probiotique(s)
EP1634599A1 (en) 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
US20060088574A1 (en) 2004-10-25 2006-04-27 Manning Paul B Nutritional supplements
EP2308566B1 (en) 2005-04-08 2017-07-05 The Procter and Gamble Company Use of orally administered probiotic bifidobacteria for human beauty benefits
US20060270739A1 (en) 2005-04-28 2006-11-30 Trustees Of Tufts College Synergistic effects of docosahexaenoic acid (DHA) and carotenoid absorption on macular pigmentation
US20060246146A1 (en) 2005-04-29 2006-11-02 Mcmahon Robert J Method of increasing the salivary sialic acid content in a mammal
US20060247153A1 (en) 2005-04-29 2006-11-02 Mcmahon Robert J Method of improving learning and memory in mammals
US9179702B2 (en) 2005-07-13 2015-11-10 Abbott Laboratories Liquid nutritional compositions containing unsaturated fatty acids
CN1933390B (zh) 2005-09-15 2014-08-13 三星电子株式会社 在正交频分多址通信系统中生成帧的方法
EP1776877A1 (en) 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
US7829126B2 (en) 2005-10-26 2010-11-09 Abbott Laboratories Infant formulas containing docosahexaenoic acid and lutein
BRPI0618261A2 (pt) 2005-11-04 2011-08-23 Arla Foods Amba concentrado e composição derivados de um produto de leite enriquecido em sialil-lactose que ocorre naturalmente, processo para preparação dos mesmos e produto
WO2007058523A1 (en) 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
CN101415461A (zh) 2006-01-09 2009-04-22 儿童医院医疗中心 用于治疗各种疾病的脂连蛋白
WO2007084507A2 (en) 2006-01-13 2007-07-26 The Scripps Research Institute [ψ[CH2NH]PG4] GLYCOPEPTIDE ANTIBIOTIC ANALOGS
EP3398606B1 (en) 2006-01-19 2021-09-15 Algenist Holdings, Inc, Microalgae-derived compositions for improving the health and appearance of skin
US9005682B2 (en) 2006-03-07 2015-04-14 Nestec S.A. Synbiotic mixture
JP2009529574A (ja) 2006-03-10 2009-08-20 エヌ．ブイ．・ヌートリシア 誕生後に乳児に最良の始まりを与えるための難消化性糖類の使用
EP2363028A1 (en) 2006-03-23 2011-09-07 Nestec S.A. High-calorie nutritional supplement
US20100234286A1 (en) 2006-03-23 2010-09-16 N.V. Nutricia Preterm formula
US20070255598A1 (en) 2006-03-29 2007-11-01 Mccarthy Nancy J Compliance aid, kits comprising the compliance aid, and methods of use
WO2007114683A1 (en) 2006-03-30 2007-10-11 N.V. Nutricia Milk oligosaccharides for stimulating the immune system
EP2021011A2 (en) 2006-05-26 2009-02-11 Nestec S.A. Methods of use and nutritional compositions of touchi extract
US20080003329A1 (en) 2006-06-30 2008-01-03 Ricardo Rueda Enriched infant formulas
US20080003330A1 (en) 2006-06-30 2008-01-03 Ricardo Rueda Infant formulas for early brain development
US8691213B2 (en) 2006-08-04 2014-04-08 SHS International Protein free formula
EP1887017A1 (en) 2006-08-09 2008-02-13 Friesland Brands B.V. Prebiotic carbohydrate
WO2008033520A2 (en) 2006-09-15 2008-03-20 The Regents Of The University Of California Bifidobacterial gene sequences and their use
US20080089981A1 (en) 2006-10-17 2008-04-17 N.V. Nutricia Ketogenic diet
NL1032840C2 (nl) 2006-11-09 2008-05-13 Friesland Brands Bv Probiotische hydrolysaatvoeding voor kinderen.
NL1033521C2 (nl) 2007-03-08 2008-09-09 Friesland Brands Bv Kindervoedingen met geoptimaliseerde aminozuursamenstelling.
WO2008111832A1 (en) 2007-03-13 2008-09-18 N.V. Nutricia Method of improving skills with a composition comprising non-digestible saccharide
NL1033698C2 (nl) 2007-04-16 2008-10-20 Friesland Brands Bv Functioneel serumeiwitproduct voor toepassing in kindervoeding en therapeutische samenstellingen, en werkwijzen ter bereiding daarvan.
JP2010524844A (ja) 2007-04-26 2010-07-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 認知症のためのシンナミド化合物
US8197872B2 (en) 2007-05-17 2012-06-12 The Regents Of The University Of California Human milk oligosaccharides to promote growth of beneficial gut bacteria
WO2008153377A1 (en) 2007-06-15 2008-12-18 N.V. Nutricia Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide
MX2010002562A (es) 2007-09-07 2011-04-11 Inst Nac De Ciencias Medicas Y Nutricion Uso de los niveles de antigeno secretor, de lewis y de sialilo como predictores para enfermedad.
JP2009075285A (ja) 2007-09-20 2009-04-09 Fujifilm Corp 半導体デバイスの剥離液、及び、剥離方法
US10251899B2 (en) 2007-10-08 2019-04-09 Mead Johnson Nutrition Company Method for improving stool characteristics in infants
US20090118229A1 (en) 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods
EP2060257A1 (en) 2007-11-08 2009-05-20 Nestec S.A. Prevention and treatment of secondary infections following viral infection
CN101909636A (zh) 2007-11-08 2010-12-08 雀巢产品技术援助有限公司 包含n-乙酰基乳糖胺的寡糖用于使新生儿免疫应答成熟的应用
WO2009067000A1 (en) 2007-11-20 2009-05-28 N.V. Nutricia Composition with synbiotics
US8273709B2 (en) 2007-12-14 2012-09-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic HCV serine protease inhibitors
EP2072052A1 (en) 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
WO2009102193A1 (en) 2008-02-12 2009-08-20 N.V. Nutricia A composition comprising bifidobacterium infantis and fructo- and galacto-oligosaccharides for the prevention of intestinal discomfort in infants
NL2001377C2 (nl) 2008-03-14 2009-09-15 Friesland Brands Bv Werkwijze voor het isoleren van siaalzuur bevattende oligosachariden, alsmede de hiermee verkrijgbare siaalzuur bevattende oligosachariden bevatttende samenstellingen.
EA020023B1 (ru) 2008-03-18 2014-08-29 Александр Владимирович ДИКОВСКИЙ Фармацевтическая композиция и способ профилактики дисбиозов, ассоциированных с энтеральным приемом антибиотиков
EP2127661A1 (en) 2008-05-27 2009-12-02 Nestec S.A. Probiotics to improve gut microbiotica
EP2143341A1 (en) 2008-07-08 2010-01-13 Nestec S.A. Nutritional Composition Containing Oligosaccharide Mixture
GB0809921D0 (en) 2008-05-30 2008-07-09 Clasado Inc Product and process therefor
WO2010023178A1 (en) 2008-08-28 2010-03-04 Chr. Hansen A/S Pharmaceuticals comprising a bacterial polysaccharide
WO2010065652A1 (en) 2008-12-02 2010-06-10 Prolacta Bioscience, Inc. Human milk permeate compositions and methods of making and using same
MX2011006371A (es) 2008-12-19 2011-09-27 Jennewein Biotechnologie Gmbh Sintesis de compuestos fucosilados.
US8425955B2 (en) 2009-02-12 2013-04-23 Mead Johnson Nutrition Company Nutritional composition with prebiotic component
CA2760999A1 (en) 2009-03-13 2010-09-16 Mariana Barboza Prebiotic oligosaccharides
AU2010233770A1 (en) 2009-04-07 2011-10-27 Glycom A/S Novel method for the synthesis of a trisaccharide
CA2761444C (en) 2009-05-11 2018-04-24 Nestec S.A. Lactobacillus johnsonii la1 ncc533 (cncm i-1225) and immune disorders
TWI381845B (zh) 2009-05-21 2013-01-11 Univ Nat Taiwan 預防和治療幽門螺旋桿菌感染的組成物
WO2011005681A1 (en) 2009-07-06 2011-01-13 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
EP4197542A1 (en) 2009-07-15 2023-06-21 N.V. Nutricia Fucosyllactose as breast milk identical non-digestible oligosaccharide for use in enhancing vaccination response
US9259447B2 (en) 2009-07-30 2016-02-16 Dupont Nutrition Biosciences Aps Lactic acid bacteria and bifidobacteria for treating endotoxemia
US20110027412A1 (en) 2009-07-31 2011-02-03 Kris Eugene Spence Compositions and Methods for Promoting Gastrointestinal and/or Cardiovascular Health
CN102481323A (zh) 2009-07-31 2012-05-30 雀巢产品技术援助有限公司 含有益生菌和所选营养物的用于母乳喂养的婴幼儿或宠物的营养组合物
US20120122906A1 (en) 2009-08-27 2012-05-17 Kowa Company, Ltd. Novel sulfonamide derivative and pharmaceutical product containing same
BR112012017978A2 (pt) 2010-01-19 2016-05-03 Abbott Lab fórmulas nutricionais contendo simbióticos
NL2004201C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides to modulate the immune system.
EP2563165A1 (en) 2010-04-27 2013-03-06 N.V. Nutricia Use of 6'-sialyl lactose in infant and toddler nutrition
WO2011136636A1 (en) 2010-04-27 2011-11-03 N.V. Nutricia Use of 6'-sialyl lactose in infant nutrition
WO2012009315A2 (en) 2010-07-12 2012-01-19 The Regents Of The University Of California Bovine milk oligosaccharides
EP2455387A1 (en) 2010-11-23 2012-05-23 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
EP2465509A1 (en) * 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharide composition for treating acute respiratory tract infections
EP2454948A1 (en) 2010-11-23 2012-05-23 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
EP2465507A1 (en) 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharide composition for treating skin diseases
EP2465508A1 (en) 2010-11-23 2012-06-20 Nestec S.A. Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases
SG191394A1 (en) 2010-12-31 2013-08-30 Abbott Lab Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
EP2658548B1 (en) 2010-12-31 2018-02-21 Abbott Laboratories Human milk oligosaccharides for modulating inflammation
EP2658400A2 (en) 2010-12-31 2013-11-06 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
MY197622A (en) 2010-12-31 2023-06-28 Abbott Lab Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
EP2658402A1 (en) 2010-12-31 2013-11-06 Abbott Laboratories Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
EP3335576A1 (en) 2010-12-31 2018-06-20 Abbott Laboratories Human milk oligosaccharides to promote growth of beneficial bacteria
US8802650B2 (en) 2010-12-31 2014-08-12 Abbott Laboratories Methods of using human milk oligosaccharides for improving airway respiratory health
WO2012092153A1 (en) 2010-12-31 2012-07-05 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
WO2012158517A1 (en) 2011-05-13 2012-11-22 Glycosyn LLC The use of purified 2'-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics
US20130012472A1 (en) 2011-07-05 2013-01-10 Boston College Composition and methods of inhibiting gastrointestinal pathogen infection
MY182335A (en) 2011-07-22 2021-01-19 Abbott Lab Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
US10639319B2 (en) 2011-08-29 2020-05-05 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
AU2012324985B2 (en) 2011-10-18 2016-01-07 Société des Produits Nestlé S.A. Composition for use in the promotion of intestinal angiogenesis and of nutrient absorption and of enteral feeding tolerance and/or in the prevention and/or treatment of intestinal inflammation and/or in the recovery after intestinal injury and surgery
GB201206599D0 (en) 2012-04-13 2012-05-30 Univ Manchester Probiotic bacteria
DE202013012827U1 (de) 2012-06-14 2020-02-13 Glycom A/S Verbesserung der Stabilität und Reinheit sowie Erhöhung der Bioverfügbarkeit von menschlichen Milch-Oligosacchariden oder Vorläufern oder Mischungen davon
EP3268019A4 (en) 2015-03-13 2018-10-31 Evolve Biosystems, Inc. Compositions that metabolize or sequester free sugar monomers and uses thereof
US10314867B2 (en) 2015-04-23 2019-06-11 Compagnie Gervais Danone Composition for reducing intestinal gas production
WO2017021479A1 (en) 2015-08-04 2017-02-09 Nestec S.A. Nutritional compositions and infant formulas comprising bifidobacterium animalis ssp. lactis and optionally a mix of oligosaccharides for inducing a gut microbiota close to the one of breast fed infants
CN108367034A (zh) 2015-10-19 2018-08-03 株式会社明治 面向婴儿的感染防御剂
CA3002509A1 (en) 2015-10-19 2017-04-27 Meiji Co., Ltd. Anti-allergic agent for infants
US20200046782A1 (en) 2016-03-11 2020-02-13 Evolve Biosystems Inc. Transient Commensal Microorganism for Improving Gut Health
EP3426269A4 (en) 2016-03-11 2019-10-16 Evolve Biosystems Inc. FOOD COMPOSITIONS FOR DEHUMIDIFICATION
EP3443969B1 (en) 2016-04-13 2021-12-22 Meiji Co., Ltd. Use of bifidobacteria for improving developmental quotient in neonates
GB201611486D0 (en) 2016-06-30 2016-08-17 Promovita Ingredients Ltd Composition for treatment and/or nutrition of poultry
CN109475169A (zh) 2016-07-01 2019-03-15 进化生物系统股份有限公司 促进哺乳动物免疫系统成熟的方法
WO2018067002A1 (en) 2016-10-05 2018-04-12 N.V. Nutricia Normalization of the intestinal microbiota composition in infants or toddlers fed with an amino acid-based nutritional composition
CN110267669A (zh) 2016-12-06 2019-09-20 潘德勒姆治疗公司 与分离并纯化的微生物有关的方法和组合物
WO2018112366A1 (en) 2016-12-15 2018-06-21 The Regents Of The University Of California Oral composition comprising lactic acid bacteria for regulating immune responses and methods related thereto
US20180200312A1 (en) 2017-01-17 2018-07-19 The Regents Of The University Of California Methods and Compositions for Enhancing Memory and/or Reducing Fear and/or Pain of a Host by Administering a Probiotic
KR102089836B1 (ko) 2017-03-15 2020-03-16 (주)바이오일레븐 트립토판분해효소 음성균과 인터페론 감마 형성을 유도하는 균주를 이용한 염증성 질환 예방 및 치료용 약학적 조성물 또는 이를 이용한 치료방법
JP2018177703A (ja) 2017-04-14 2018-11-15 株式会社明治 Ｔｏｌｌ様受容体２活性化用組成物
WO2019000098A1 (en) 2017-06-30 2019-01-03 Wilfrid Laurier University THERMOSIPHON FILLED WITH LIQUID TO A FORCED CIRCULATION PHASE
EP3681521A4 (en) 2017-09-13 2021-05-19 Evolve Biosystems Inc. METABOLOMIC REVIEW OF MAMMAL INFANTS

Also Published As

Publication number Publication date
WO2012092156A1 (en) 2012-07-05
CA2822219C (en) 2020-12-29
US20120172319A1 (en) 2012-07-05
NZ611807A (en) 2015-02-27
US9539269B2 (en) 2017-01-10
BR112013016905A2 (pt) 2019-09-24
US11179406B2 (en) 2021-11-23
CA2822219A1 (en) 2012-07-05
SG10202110501RA (en) 2021-11-29
SG191392A1 (en) 2013-08-30
US20200093846A1 (en) 2020-03-26
MY197622A (en) 2023-06-28
EP2658547A1 (en) 2013-11-06
US10471081B2 (en) 2019-11-12
CN107019701B (zh) 2020-07-28
US20230338404A1 (en) 2023-10-26
CN103338775A (zh) 2013-10-02
US20200078385A1 (en) 2020-03-12
CN107019701A (zh) 2017-08-08
SG10201603856PA (en) 2016-07-28
MX2013007692A (es) 2013-08-15
US20170224714A1 (en) 2017-08-10
MY171620A (en) 2019-10-21
MX2020010780A (es) 2020-10-28
US11690859B2 (en) 2023-07-04

Similar Documents

Publication Publication Date Title
MX2022011064A (es) Metodos para disminuir la incidencia de la enterocolitis necrotizante en bebes, infantes, o ni?os al usar los oligosacaridos de leche humana.
PH12017500874A1 (en) Human milk oligosaccharides for modulating inflammation
MX338174B (es) Metodos para reducir la incidencia de la tension oxidativa al usar los oligosacaridos de leche humana, la vitamina c y los agentes antiinflamatorios.
MY169326A (en) Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
MY174541A (en) Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
HK1174800A1 (en) Products for decreasing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome in an infant, toddler, or child
MX2021014138A (es) Metodos para usar los oligosacaridos de leche humana para mejorar la salud respiratoria de las vias aereas.
MX352040B (es) Formulaciones nutricionales que incluyen los oligosacaridos de leche humana y los acidos grasos poliinsaturados de cadena larga y usos de las mismas.
MX2018005297A (es) Formula pediatrica sintetica para estimular celulas nerviosas entericas en el tracto gastrointestinal.
MX2013007675A (es) Combinacion simbiotica de oligosacaridos probioticos y de leche humana para promover el crecimiento de la microbiota beneficiosa.
MX2014000895A (es) Galacto-oligosacaridos para prevenir lesion y/o promover cicatrizacion del tracto gastrointestinal.
PH12016500772A1 (en) Synthetic milk compositions comprising n-6 eicosatrienoic acid and polar lipids for infants younger and older than three months for healthy establishment of cognitive function
PH12017500873A1 (en) Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides